According โto a report in The Lancet, the new name, polyendocrine metabolic ovarian โ syndrome, or PMOS, was chosen by a global coalition of patients, clinicians, and medical organizations to better reflect the โ conditionโs wide-ranging hormonal and metabolic impacts.
The focus โon ovarian cysts has led to delays in diagnoses and fragmented care, while the new name aims to improve how the โ condition is detected, treated, and explained, the researchers said.
Symptoms of PMOS include irregular or absent โmenstrual cycles, infertility, pregnancy complications, excess hair growth, acne, anxiety and depression, โweight โgain, obesity, diabetes and other disturbances in insulin, and cardiovascular disease.
Tap the link to learn more about the โ transition to the new terminology.
https://mdsc.pe/4uNjedR
Ref; Medscape
